Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 309

1.

Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: a network meta-analysis.

Zhang SH, Liu GF, Li XF, Liu L, Yu SN.

J Cell Physiol. 2017 Sep 19. doi: 10.1002/jcp.26183. [Epub ahead of print]

PMID:
28926090
2.

Chemotherapy for advanced gastric cancer.

Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S.

Cochrane Database Syst Rev. 2017 Aug 29;8:CD004064. doi: 10.1002/14651858.CD004064.pub4. Review.

PMID:
28850174
3.

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.

Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH, Bekaii-Saab T.

Cancer. 2017 Aug 17. doi: 10.1002/cncr.30927. [Epub ahead of print]

PMID:
28817187
4.

Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: A systematic review.

Akinwande O, Dendy M, Ludwig JM, Kim HS.

Surg Oncol. 2017 Sep;26(3):268-275. doi: 10.1016/j.suronc.2017.05.003. Epub 2017 May 22. Review.

PMID:
28807246
5.

Oral versus intravenous fluoropyrimidines for colorectal cancer.

Chionh F, Lau D, Yeung Y, Price T, Tebbutt N.

Cochrane Database Syst Rev. 2017 Jul 28;7:CD008398. doi: 10.1002/14651858.CD008398.pub2. Review.

PMID:
28752564
6.

S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.

Zhong S, Qie S, Yang L, Yan Q, Ge L, Wang Z.

Medicine (Baltimore). 2017 Jul;96(30):e7611. doi: 10.1097/MD.0000000000007611. Review.

7.

Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.

Han D, Wang G, Sun L, Ren X, Shang W, Xu L, Li S.

Eur J Cancer Care (Engl). 2017 Jul 13. doi: 10.1111/ecc.12723. [Epub ahead of print]

PMID:
28707433
8.

Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.

Cinar P, Ko AH.

Chin Clin Oncol. 2017 Jun;6(3):29. doi: 10.21037/cco.2017.06.13.

9.

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis.

van Helden EJ, Menke-van der Houven van Oordt CW, Heymans MW, Ket JCF, van den Oord R, Verheul HMW.

Cancer Metastasis Rev. 2017 Jul 10. doi: 10.1007/s10555-017-9668-y. [Epub ahead of print] Review.

10.

The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.

Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M, Hoyle M.

Health Technol Assess. 2017 Jun;21(38):1-294. doi: 10.3310/hta21380.

11.

Toxicity of Chemotherapy Regimens in Advanced and Metastatic Pancreatic Cancer Therapy: A Network Meta-Analysis.

Wang XF, Huang WF, Nie J, Zhou Y, Tan DW, Jiang JH.

J Cell Biochem. 2017 Jul 6. doi: 10.1002/jcb.26266. [Epub ahead of print]

PMID:
28681936
12.

Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review.

Petrelli F, Inno A, Ghidini A, Rimassa L, Tomasello G, Labianca R, Barni S; GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) and Cremona Hospital.

Eur J Cancer. 2017 Aug;81:174-182. doi: 10.1016/j.ejca.2017.05.025. Review.

PMID:
28633088
13.

Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.

Liu GF, Li GJ, Zhao H.

J Cell Biochem. 2017 Jun 13. doi: 10.1002/jcb.26210. [Epub ahead of print]

PMID:
28608558
14.

Treatment options for metastatic colorectal cancer in patients with liver dysfunction due to malignancy.

Faugeras L, Dili A, Druez A, Krug B, Decoster C, D'Hondt L.

Crit Rev Oncol Hematol. 2017 Jul;115:59-66. doi: 10.1016/j.critrevonc.2017.03.029. Epub 2017 Mar 29. Review.

15.

Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?

Aprile G, Negri FV, Giuliani F, De Carlo E, Melisi D, Simionato F, Silvestris N, Brunetti O, Leone F, Marino D, Santini D, Dell'Aquila E, Zeppola T, Puzzoni M, Scartozzi M.

Crit Rev Oncol Hematol. 2017 Jul;115:1-12. doi: 10.1016/j.critrevonc.2017.03.025. Epub 2017 Apr 20. Review.

PMID:
28602164
16.

UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.

Zhang X, Yin JF, Zhang J, Kong SJ, Zhang HY, Chen XM.

Cancer Chemother Pharmacol. 2017 Jul;80(1):135-149. doi: 10.1007/s00280-017-3344-3. Epub 2017 Jun 5. Review.

PMID:
28585035
17.

FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.

Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S.

JAMA Oncol. 2017 Jul 13;3(7):e170278. doi: 10.1001/jamaoncol.2017.0278. Epub 2017 Jul 13. Review.

PMID:
28542671
18.

The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis.

Li M, Song X, Zhu J, Fu A, Li J, Chen T.

Clin Neurol Neurosurg. 2017 Aug;159:6-12. doi: 10.1016/j.clineuro.2017.05.015. Epub 2017 May 11.

PMID:
28514722
19.

UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.

Chen X, Liu L, Guo Z, Liang W, He J, Huang L, Deng Q, Tang H, Pan H, Guo M, Liu Y, He Q, He J.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1109-1117. doi: 10.1007/s00280-017-3306-9. Epub 2017 May 13. Review.

PMID:
28502040
20.

FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Leal F, Ferreira FP, Sasse AD.

Clin Colorectal Cancer. 2017 Mar 24. pii: S1533-0028(16)30244-4. doi: 10.1016/j.clcc.2017.03.012. [Epub ahead of print]

PMID:
28433602

Supplemental Content

Loading ...
Support Center